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METHODS: We reviewed years 1987-2013 of the Mayo Clinic RP Registry to identify men with Body Mass Index (BMI) information available. Men who underwent PCa treatment prior to RP and men with metastatic disease at RP were excluded. Patients were grouped into four BMI categories: < 25, 25-29.9, 30-34.9 , and > 35. BMI > 30 was defined as obese. Standard descriptive statistics compared baseline characteristics, while forced entry multivariable cox proportional hazard models assessed the association of BMI with metastasis and prostate cancer mortality (PCM). Multivariable models were adjusted for pre-RP PSA, pathologic Gleason Score, pT stage, pN stage, margin status, age, adjuvant hormone therapy, adjuvant radiation, year of surgery, and open vs robotic approach.
RESULTS: In our cohort of 18,039 men (median follow-up 9.3 years after RP), 20.6% (3,707), 51.9% (9,348), 21.9% (3,936) and 5.6% (1,016) had a BMI < 25, 25-29.9, 30-34.9 , and > 35, respectively. Higher BMI categories had higher rates of pathologic Gleason Score 7-10 disease: 38.7%, 40.7%, 46.1%, 54.0%, respectively (p<0.001). Obese patients also had higher positive margin rates: 23.4%, 26.3%, 30.1%, 31.9%, respectively (p<0.001). PSA, pT stage, pN stage, and adjuvant therapy did not significantly differ between BMI categories (p>0.05). Log Rank comparisons found higher Kaplan-Meier rates of metastasis and PCM for patients with a BMI of 30-34.9 and > 35 (p<0.05 for all). On multivariable cox regression for metastasis, patients with a BMI 30-34.9 (HR 1.307, 95% CI 1.073-1.592, p¼0.008) and BMI > 35 (HR 1.421, 95% CI 1.071-1.886, p¼0.015) had an increased risk of metastasis relative to patients with a BMI < 25. Similarly, patients with a BMI 30-34.9 (HR 1.323, 95% 1.010-1.733, p¼0.042) and BMI > 35 (HR 1.620, 95% CI 1.098-2.392, p¼0.015) had higher PCM rates relative to patients with BMI < 25 on multivariable analysis. CONCLUSIONS: Our data supports an independent association between BMI and PCa metastasis and cancer-specific mortality after RP. There was a direct increase in the odds of metastasis and PCM between the BMI 30-34.9 and BMI > 35 groups, further strengthening this link. Further study is warranted to determine if weight loss can abrogate this effect of obesity on PCa recurrence after RP. METHODS: HRQOL surveys were completed at baseline, 3 and 12 months after surgery. The general and prostate-specific sections of HRQOL were assessed with Medical Outcomes Study 36 e Item Short Form (SF-36) and University of California, Los Angeles Prostate Cancer Index (UCLA e PCI) respectively. RESULTS: The surveys were returned by 126 (76%) and 111 (67%) men after 3 and 12 months, respectively. Adjuvant radiotherapy was performed in 10 (9%) patients. Only patients without adjuvant treatment (radiotherapy or hormonotherapy) were included in the analysis, resulting in a final study cohort of 101 patients (71 and 30 for the TERP and EERP, respectively). The median patients age in TERP and EERP group was 62.0 and 64 years, respectively. There is no significant difference QOL scores for the baseline, after 3 months and 12 months after operation in each group. In the EERP group Mental Health improved over the baseline after 12 months. In the TERP group Mental health and Social functioning improved over the baseline after 12 months. In the rest of domains QOL scores did not change after 12 months in both groups. For the baseline score, at 3 months and 12 months there was no significant difference between the EERP and TERP groups except for sexual function that was worse in the EERP group at baseline. Urinary function, urinary bother, sexual function and sexual bother had not returned to baseline at 12 months in both groups. Bowel function and bother was not different after 12 months in each group. At 12 months after ERP 41 (58%) and 17 (54%) men did not use any pads for 24 hours in TERP and EERP group, respectively CONCLUSIONS: Endoscopic, extraperitoneal and transperitoneal radical prostatectomies with extended pelvic lymph node dissection do not alter patients reported health related quality of life. No significant differences were found between the two treatment groups. We could attributed that aggressive treatment of PCa do not more compromise HRQOL. METHODS: Twelve prostate cancer patients with normal preoperative erectile and urinary function were enrolled in an IRB approved single arm pilot study to receive RARP with unilateral cavernous nerve reconstruction using processed nerve allograft. Patients were followed for 24 months after surgery. Erectile and urinary functional recovery was measured using the International Index of Erectile Function-EF domain (IIEF-6) and the Expanded Prostate cancer Index Composite (EPIC, Version 2.2002) questionnaires. Possible adverse events related to nerve graft implantation were assessed. RESULTS: Planned surgery was successfully performed in all 12 patients by a single surgeon without any attributed complications or adverse events. The implantation procedure extended operation time by16 AE 4.3 minutes. Two patients received androgen deprivation therapy post-operatively and were excluded from analysis. Partial recovery of erectile function (IIEF !13) was seen in 50% and 70% of patients by 12 and 24 months after surgery respectively, while recovery of potency (erection firm enough for intercourse, IIEF !22) was achieved in 50% of patients 24 months after surgery. Urinary continence (0-1 pad used per day) was restored in 75%, 83.3% and 91.7% of patients by 6, 12 and 24 months after surgery, respectively.
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